NCT06826430 - Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2027

Conditions

Autoimmune Thrombocytopenia

Interventions

DRUG

Inaticabtagene autoleucel Injection

Inaticabtagene autoleucel Injection, the autologous 2nd generation CD19-directed CAR-T cells, will be administered by vein. Before CAR-T infusion，patients will get a 3-4 days lymphodepletion therapy with fludarabine and cyclophosphamide.

Trial Locations (1)

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing